Effects of Prime-boost Strategies on the Protective Efficacy and Immunogenicity of a PLGA (85:15)-encapsulated Chlamydia Recombinant MOMP Nanovaccine

Overview

Journal Pathog Dis

Publisher Oxford University Press

Specialties Infectious Diseases
Microbiology

Date 2024 Jun 11

PMID 38862192

Authors

Rajnish Sahu

Richa Verma

Timothy E Egbo

Guillermo H Giambartolomei

Shree R Singh

Vida A Dennis

Affiliations

Soon will be listed here.

Abstract

To begin to optimize the immunization routes for our reported PLGA-rMOMP nanovaccine [PLGA-encapsulated Chlamydia muridarum (Cm) recombinant major outer membrane protein (rMOMP)], we compared two prime-boost immunization strategies [subcutaneous (SC) and intramuscular (IM-p) prime routes followed by two SC-boosts)] to evaluate the nanovaccine-induced protective efficacy and immunogenicity in female BALB/c mice. Our results showed that mice immunized via the SC and IM-p routes were protected against a Cm genital challenge by a reduction in bacterial burden and with fewer bacteria in the SC mice. Protection of mice correlated with rMOMP-specific Th1 (IL-2 and IFN-γ) and not Th2 (IL-4, IL-9, and IL-13) cytokines, and CD4+ memory (CD44highCD62Lhigh) T-cells, especially in the SC mice. We also observed higher levels of IL-1α, IL-6, IL-17, CCL-2, and G-CSF in SC-immunized mice. Notably, an increase of cytokines/chemokines was seen after the challenge in the SC, IM-p, and control mice (rMOMP and PBS), suggesting a Cm stimulation. In parallel, rMOMP-specific Th1 (IgG2a and IgG2b) and Th2 (IgG1) serum, mucosal, serum avidity, and neutralizing antibodies were more elevated in SC than in IM-p mice. Overall, the homologous SC prime-boost immunization of mice induced enhanced cellular and antibody responses with better protection against a genital challenge compared to the heterologous IM-p.

Citing Articles

Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment.

Chen C, Xu Y, Meng H, Bao H, Hu Y, Li C Nanomaterials (Basel). 2025; 15(2).

PMID: 39852737 PMC: 11767563. DOI: 10.3390/nano15020122.

References

Ols S, Yang L, Thompson E, Pushparaj P, Tran K, Liang F . Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. Cell Rep. 2020; 30(12):3964-3971.e7. PMC: 7198771. DOI: 10.1016/j.celrep.2020.02.111. View

Singh S, Hulett K, Pillai S, Dennis V, Oh M, Scissum-Gunn K . Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine. 2005; 24(8):1213-24. DOI: 10.1016/j.vaccine.2005.08.097. View

Li W, Murthy A, Guentzel M, Seshu J, Forsthuber T, Zhong G . Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008; 180(5):3375-82. DOI: 10.4049/jimmunol.180.5.3375. View

Pal S, Tifrea D, Follmann F, Andersen P, de la Maza L . The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. Vaccine. 2017; 35(13):1705-1711. DOI: 10.1016/j.vaccine.2017.02.020. View

Farris C, Morrison S, Morrison R . CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun. 2010; 78(10):4374-83. PMC: 2950360. DOI: 10.1128/IAI.00622-10. View

Noormehr H, Zavaran Hosseini A, Soudi S, Beyzay F . Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle. Int Immunopharmacol. 2018; 59:97-105. DOI: 10.1016/j.intimp.2018.03.012. View

Moore-Connors J, Fraser R, Halperin S, Wang J . CD4⁺CD25⁺Foxp3⁺ regulatory T cells promote Th17 responses and genital tract inflammation upon intracellular Chlamydia muridarum infection. J Immunol. 2013; 191(6):3430-9. DOI: 10.4049/jimmunol.1301136. View

de la Maza L, Zhong G, Brunham R . Update on Chlamydia trachomatis Vaccinology. Clin Vaccine Immunol. 2017; 24(4). PMC: 5382834. DOI: 10.1128/CVI.00543-16. View

Stary G, Olive A, Radovic-Moreno A, Gondek D, Alvarez D, Basto P . VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015; 348(6241):aaa8205. PMC: 4605428. DOI: 10.1126/science.aaa8205. View

10.

Manam S, Chaganty B, Evani S, Zafiratos M, Ramasubramanian A, Arulanandam B . Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice. PLoS One. 2013; 8(5):e64917. PMC: 3669087. DOI: 10.1371/journal.pone.0064917. View

11.

Ekong E, Okenu D, Mania-Pramanik J, He Q, Igietseme J, Ananaba G . A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol Med Microbiol. 2008; 55(2):280-91. PMC: 3062614. DOI: 10.1111/j.1574-695X.2008.00493.x. View

12.

Lin W, Pan C, Adams R, Laube B, Griffin D . Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA. mBio. 2014; 5(2):e01047. PMC: 3993862. DOI: 10.1128/mBio.01047-14. View

13.

Khademi F, Yousefi A, Derakhshan M, Najafi A, Tafaghodi M . Enhancing immunogenicity of novel multistage subunit vaccine of using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration. Iran J Basic Med Sci. 2019; 22(8):893-900. PMC: 6760476. DOI: 10.22038/ijbms.2019.33962.8079. View

14.

Huynh D, Jong W, Koningstein G, van Ulsen P, Luirink J . Overexpression of the Bam Complex Improves the Production of MOMP in the Outer Membrane. Int J Mol Sci. 2022; 23(13). PMC: 9266984. DOI: 10.3390/ijms23137393. View

15.

Low N, Redmond S, Uuskula A, van Bergen J, Ward H, Andersen B . Screening for genital chlamydia infection. Cochrane Database Syst Rev. 2016; 9:CD010866. PMC: 6457643. DOI: 10.1002/14651858.CD010866.pub2. View

16.

Sahu R, Dixit S, Verma R, Duncan S, Coats M, Giambartolomei G . A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4 effector (CD44 CD62L) and memory (CD44 CD62L) T-cells in immunized mice. Nanomedicine. 2020; 29:102257. PMC: 10198673. DOI: 10.1016/j.nano.2020.102257. View

17.

Holmgren J, Nordqvist S, Blomquist M, Jeverstam F, Lebens M, Raghavan S . Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant. Vaccine. 2018; 36(41):6223-6230. DOI: 10.1016/j.vaccine.2018.07.073. View

18.

Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A . Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen,.... Vaccine. 2013; 31(20):2457-64. DOI: 10.1016/j.vaccine.2013.03.027. View

19.

Berry L, Hickey D, Skelding K, Bao S, Rendina A, Hansbro P . Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun. 2004; 72(2):1019-28. PMC: 321610. DOI: 10.1128/IAI.72.2.1019-1028.2004. View

20.

Pal S, Slepenkin A, Felgner J, Davies D, Felgner P, de la Maza L . Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with . Pathogens. 2023; 12(7). PMC: 10383793. DOI: 10.3390/pathogens12070863. View